Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD -1.63%50 Forward PE Ratio is 27.33 as of Jul. 31, 2026. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.97 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 314 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 65.92% on this metric.
ABL Diagnostics (XPAR:ABLD) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
ABL Diagnostics Forward PE Ratio Related Terms
ABL Diagnostics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics Forward PE Ratio Chart
ABL Diagnostics Annual Data
Trend
2025-12
Forward PE Ratio
51.67
ABL Diagnostics Semi-Annual Data
2025-06
2025-12
Forward PE Ratio
90.00
51.67
XPAR:ABLD vs VEEV, BTSG, HQY: Forward PE Ratio Comparison
For the Health Information Services subindustry, ABL Diagnostics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
ABL Diagnostics (XPAR:ABLD) has a Forward PE Ratio of 27.33 as of Jul. 31, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #207 out of 314 companies in the Healthcare Providers & Services industry, placing it in the top 65.9%.
Is ABL Diagnostics' Forward PE Ratio too high?
ABL Diagnostics' current Forward PE Ratio is 27.33. The Healthcare Providers & Services industry median Forward PE Ratio is 18.21. ABL Diagnostics' value of 27.33 is 50.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #207 out of 314 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #207 out of 314 companies for Forward PE Ratio. This places ABL Diagnostics in the lower half of its industry. The industry median Forward PE Ratio is 18.21. ABL Diagnostics' value of 27.33 is 50.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.21, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Forward PE Ratio of 27.33 is 50.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Forward PE Ratio is 27.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.97, compared to a current price of €2.42 — trading 69.6% below its estimated fair value. The current Forward PE Ratio is 27.33 and 50.1% above the Healthcare Providers & Services industry median of 18.21. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Forward PE Ratio is 27.33 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.42 is trading 69.6% below its estimated GF Value™ of €7.97.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Forward PE Ratio: 27.33
GF Value™: €7.97 vs. price of €2.42 (69.6% below fair value)
Industry Position: 50.1% above the Healthcare Providers & Services median (#207 of 314)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
